Therapeutic Asset Ratings

361 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Humulin R Obesity	University of Missouri-Columbia	P4	B (61)
Losartan Obesity	RenJi Hospital	P4	B (61)
Mirabegron Obesity	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P4	B (61)
Misoprostol Obesity	University of Texas at Austin	P4	B (61)
hs-20094 Obesity	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (61)
xw003 Obesity	Hangzhou Sciwind Biosciences Co., Ltd.	P3	B (61)
17-beta-estradiol Obesity	University of Colorado, Denver	P4	B (60)
APIGUARD Obesity	Centro Universitario de Ciencias de la Salud, Mexico	P4	B (60)
Bazedoxifene Obesity	VA Office of Research and Development	P4	B (60)
Capecitabine Obesity	Ikaria Bioscience Pty Ltd	P4	B (60)
Contrave Obesity	The Royal's Institute of Mental Health Research	P4	B (60)
ESTROGENS, CONJUGATED Obesity	VA Office of Research and Development	P4	B (60)
Moxonidine Obesity	Vanderbilt University Medical Center	P4	B (60)
Quinine Obesity	Universitaire Ziekenhuizen KU Leuven	P4	B (60)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Obesity	University of North Carolina, Chapel Hill	P4	B (59)
Acarbose Obesity	Empros Pharma AB	P4	B (59)
DULAGLUTIDE Obesity	Ali Aminian	P4	B (59)
Qsymia Obesity	Alvogen Korea	P4	B (59)
SIMVASTATIN Obesity	Eli Lilly and Company	P4	B (59)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Obesity	Tanta University	P4	B (58)
Doravirine Obesity	José Antonio Mata Marín	P4	B (58)
MIDAZOLAM Obesity	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P4	B (58)
RAMIFENTANYL Obesity	Siirt Training and Research Hospital	P4	B (58)
ROPIVACAINE Obesity	Ain Shams University	P4	B (58)
SACUBITRIL VALSARTAN Obesity	University of Alabama at Birmingham	P4	B (58)

Showing 51 to 75 of 361 assets

PreviousPage 3 of 15Next